Development
Recursion Pharmaceuticals, Inc.
RXRX
$5.49
$0.9220.13%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 3.40% | -4.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.40% | -4.39% | |||
| Cost of Revenue | -300.12% | 25.51% | |||
| Gross Profit | 345.56% | -31.68% | |||
| SG&A Expenses | 8.38% | 3.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.84% | 18.71% | |||
| Operating Income | -0.57% | -21.83% | |||
| Income Before Tax | -4.34% | -21.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.02% | -21.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.02% | -21.23% | |||
| EBIT | -0.57% | -21.83% | |||
| EBITDA | -0.64% | -20.74% | |||
| EPS Basic | 3.99% | -13.94% | |||
| Normalized Basic EPS | -1.47% | -13.90% | |||
| EPS Diluted | 3.99% | -13.94% | |||
| Normalized Diluted EPS | -1.47% | -13.90% | |||
| Average Basic Shares Outstanding | 4.12% | 6.41% | |||
| Average Diluted Shares Outstanding | 4.12% | 6.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||